IPAMORELIN · DECODED
Ipamorelin
Decoded · Grey Market · Research Chemical
BY THE NUMBERS
HOW IT WORKS
Selective ghrelin receptor (GHSR-1a) agonist. Stimulates GH release from the pituitary via ghrelin receptor signaling, mechanistically distinct from GHRH analogs. The selectivity limits off-target stimulation of cortisol and prolactin, which was a clinically relevant weakness of earlier GHRPs such as GHRP-2 and GHRP-6. Human trial evidence to confirm this advantage in practice remains essentially absent.
WHERE IT CAME FROM
Ipamorelin is a synthetic pentapeptide, meaning it is built from five amino acids, that was originally developed by Novo Nordisk in the 1990s. It belongs to a class of compounds called growth hormone releasing peptides, or GHRPs. GHRPs work through a different receptor than GHRH analogs like CJC-1295 or tesamorelin. They activate the ghrelin receptor, sometimes called the growth hormone secretagogue receptor, which is one of the body's two separate pathways for triggering GH release from the pituitary. Ghrelin itself is a hormone produced primarily in the stomach that signals hunger and also stimulates GH release. Ipamorelin mimics ghrelin's effect on GH release without fully mimicking its other effects.
The reason ipamorelin became the preferred GHRP in grey market use is selectivity. Earlier GHRPs like GHRP-2 and GHRP-6 stimulate GH release but also meaningfully raise cortisol and prolactin, stress and lactation hormones that users generally want to avoid. Ipamorelin raises GH with minimal effect on either. Novo Nordisk investigated it through early clinical development but ultimately discontinued the program. The compound moved into the research chemical market, where it is now widely sold and often used in combination with CJC-1295. The two compounds work through separate mechanisms, GHRH receptor and ghrelin receptor, and are thought to produce a larger combined GH pulse than either does alone.
THE STUDIES
WHAT THE STUDIES SHOW
ESTABLISHED
- ▸Activates ghrelin receptor (confirmed mechanism)
- ▸GH release in humans confirmed in Phase 1 data
- ▸Minimal effect on cortisol vs. other GHRPs
- ▸Minimal effect on prolactin vs. other GHRPs
EXTRAPOLATED
- ▸Body composition improvement (inferred from GH effects)
- ▸Recovery and sleep quality (inferred from GH pulse)
- ▸Synergistic effect with CJC-1295 (mechanistically plausible)
- ▸No direct human efficacy trial data for these endpoints
UNKNOWN
- ▸Optimal dosing frequency and amount in humans
- ▸Long-term safety with chronic use
- ▸True magnitude of GH pulse versus natural baseline
- ▸Whether combination with CJC-1295 produces meaningful clinical benefit
SIDE EFFECTS
REPORTED (ANECDOTAL / EXTRAPOLATED)
- ▸Injection site reactions
- ▸Transient headache after injection
- ▸Mild water retention
- ▸Tingling or flushing sensation
- ▸Most reports are from user experience, not controlled trials
NOTABLE / MONITOR FOR
- ▸Elevated IGF-1 with chronic use (requires monitoring)
- ▸Blood sugar effects from GH elevation
- ▸Cortisol and prolactin are less affected than other GHRPs but not zero
- ▸No controlled human safety data for long-term use
- ▸Purity and sterility risk inherent to all grey market compounds
REGULATORY STATUS
Ipamorelin has no FDA approval and no active development program working toward one. Novo Nordisk discontinued development and the compound has not been picked up by another pharmaceutical sponsor. It is sold as a research chemical through grey market vendors and is not available through any regulated pharmacy pathway. It is not on the list of bulk drug substances approved for 503A or 503B compounding. Obtaining ipamorelin means obtaining it entirely outside the regulated pharmaceutical supply chain, with no guarantee of purity, accurate concentration, or sterile preparation unless independent laboratory verification is performed.
PROS & CONS
PROS
- +Selective GH release with minimal cortisol and prolactin elevation
- +Phase 1 human data confirms the mechanism works in humans
- +Short half-life produces a pulse rather than sustained GH elevation
- +Widely studied in combination with CJC-1295 at the community level
- +Five amino acid structure is relatively simple and stable
CONS
- −No human efficacy trial for any clinical endpoint
- −No FDA approval, no regulated supply chain
- −Long-term safety is entirely unknown from a controlled evidence standpoint
- −Purity and accurate dosing cannot be verified without independent testing
- −IGF-1 elevation requires monitoring most users are not performing
- −No current pharmaceutical sponsor pursuing development toward approval
DAILY PEPTIDE VERDICT
RANKING
Ipamorelin's documented characteristic within the grey market GHRP category is selectivity: it raises GH without meaningfully raising cortisol or prolactin. That selectivity is real and documented in the Phase 1 data Novo Nordisk published. The gap is the same gap that applies to every grey market GH secretagogue: the leap from a confirmed mechanism and Phase 1 safety data to clinical benefit in healthy adults has never been made in a controlled trial. Ipamorelin does something in the body. Whether that something produces the body composition and recovery outcomes grey market users are seeking at the doses and frequencies being used is genuinely unknown. The combination with CJC-1295 is mechanistically logical but equally unproven at the efficacy level.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. Ipamorelin is sold as a research chemical and does not hold FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.